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18. THE ETIOLOGY OF NEURAL TUBE
DEFECTS

J.M. Scott, D.G. Weir, A. Molloy, J. McPartlin, 1. Daly, P. Kirke, M. Conley,
J. Lee, and J. Mills

Introduction
Evidence continues to confirm that periconceptional
ingestion of folic acid can prevent neural tube defects,
although the basis of this prevention has been unclear.
To further elucidate the mechanism by which this
occurs, blood samples were collected from more than
50,000 pregnant women and the samples analyzed
for red cell folate, plasma folate, plasma vitamin
B 12 , and plasma homocysteine levels. Based on the
results, it appears that the beneficial effect of folic
acid is in overcoming a metabolic block in a folatedependent enzyme or transport process. It is likely
that methionine synthase may be directly or indirectly involved.
The neural plate closes to form the spinal cord and
the cranium between days 24 and 28 postconception.
Incomplete closure of the former causes spina bifida;
of the latter, anencephaly. The two conditions are
called neural tube defects (NTD) [l}. Earlier evidence
that folic acid taken periconceptionally by
women could prevent NTDs (2-4} has recently
been confirmed by two randomized trials using
peri conceptional ingestion of folic acid supplements
(5,6}.
There are three possible ways by which folic acid
might exert this protective effect: (1) it might treat
folate deficiency; (2) it might overcome malabsorption; or, (3) it might overcome a metabolic block. The
future public health response to this important development would depend to a considerable extent on
which one of these three mechanisms is actually involved. If simple folate deficiency is involved, protection might be achieved at levels of folic acid far lower
than the 400 lJ,g per day used in the trials. By contrast, if folic acid overcomes malabsorption or an impairment or block in some folate-dependent enzyme
or process, the relatively high levels of folic acid used
in the trials may be essential to achieve protection.

We set out to test which of the three was the
operative alternative by collecting blood samples
from women early in pregnancy, when their folate
status would most accurately reflect that pertaining to
the time of closure of the neural tube (days 24-28
postconception). When it was subsequently ascertained which women had an NTD-affected pregnancy, blood samples were retrieved and their plasma
and red cell folates (RCFs) were compared with controls matched for length of storage. We further investigated evidence that a metabolic block in folate
metabolism actually existed in these women.

Materials and Methods
Between March 1986 and March 1990 more than
50,000 blood samples were collected at the first booking clinic from women attending the three Dublin
Maternity Hospitals (Coombe, Rotunda, and National Maternity). These three hospitals carry out
most of the deliveries in the greater Dublin area, and
the collections represented more than 70% of these,
giving a very representative cohort. Blood was collected into potassium EDTA. A sample of this whole
blood was taken and diluted 1 in 10 into 1 % ascorbic
acid in water for RCF analysis (7}. Plasma was separated by centrifugation. All samples were stored at
-20°C until analyzed. For the study, samples from
the women who had an NTD-affected pregnancy
(cases) were identified and retrieved. Samples were
also identified from a randomly selected group of
women with normal pregnancy outcomes (controls)
taken over the same period and in the same hospitals.
This resulted in 81 cases and 247 controls on which
an analysis for RCF and plasma folate was carried out
(7}. Plasma vitamin B12 levels were also estimated on
these samples (8}. Plasma homocysteine levels were
assayed by a modification of a previous method (9}'
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Results
For plasma folate, the median (range) for the cases was
3.5/-lg/L (0.7-20.8; n = 81) and for controls was
4.6/-lg/L (0.5-22.1; n = 247). Values for cases were
significantly lower (p = 0.001). Comparable results
for RCF in cases were 269/-lg/L (39-715; n = 81) and
in controls were 338/-lg/L(80-1302; n= 247). Again,
values for cases were significantly lower (p = 0.002).
Of significance is that only seven cases (8.6%) had
plasma folate levels that would be considered deficient «1.5/-lg/L) (table 18-1). Similarly, consideration of RCF values in the cases found only 11
(13.6%) with deficient values «150 /-lg/L). Likewise,
it was clear that very few cases (5 (6.1 %» had vitamin
B12 levels in the deficient range «150 ng/L) (table
18.2). Plasma folate levels were found to be a risk
factor for an NTD-affected birth [l0}. Of greater
significance was that plasma vitamin B12 levels acted
as an independent risk factor for an affected pregnancy.
There was also no correlation between the plasma
folate level and the plasma vitamin BI2 level in either
cases or controls (fig. 18-1).

TABLE 18-1. Percentage of cases
and controls that have "deficient folate
status" as determined by the usual criteria
for red cell folate and plasma folate deficiency
Deficient and normal folate levels
CASES: N

Red cell folate
(Ilg/L)
<150
>150
Plasma folate
(Ilg/L)
<1.5
>1.5

= 81

CONTROLS: N

11 (13.6%)
70 (86.4%)

7 (2.8%)
240 (97.2%)

7 (8.6%)
74 (91.4%)

10 (4.0%)
237 (96.0%)

= 247

TABLE 18-2. Percentage of cases and
controls that have deficient status as
determined at two levels of plasma vitamin BI2
Deficient and normal plasma B12 levels
CASES: N

= 82

CONTROLS: N =

Plasma B12
(ng/L)
<150
>150

5 (6.1%)
77 (93.9%)

8 (3.2%)
243 (96.8%)

<200
>200

14 (17.1%)
68 (82.9%)

26 (10.4%)
225 (89.6%)

251

The plasma homocysteine level was compared between cases and controls. This was done by dividing
each into deciles of plasma vitamin B 12 • At the lower
vitamin BI2 levels there were significantly higher
plasma homocysteine levels III the cases compared
with the controls [lI}.
DISCUSSION

There is now conclusive evidence that periconceptional supplementation of women with the vitamin
folic acid prevents the vast majority ofNTDs (5,6}. It
was not clear if this prophylaxis was brought about by
treating women who are (1) deficient in folate, (2)
overcoming an intestinal malabsorption, or whether
(3) the higher level of folic acid intake (an extra
400/-lg per day) overcomes some as yet unidentified
metabolic block in folate metabolism. We determined folate status in women who went on to have an
affected child later in their pregnancy. This was done
by determining both their plasma folate level and
their RCFs and matching them to randomly collected
controls from similar women with normal pregnancies collected and stored in a similar manner. In
nearly half of the cases and controls, blood was collected before 14 weeks postconception. The third
quarter was collected between 14-20 weeks, and the
remaining quarter at greater than 21 weeks.
Plasma folate is considered to be a reasonable index
of folate status. It is, however, subject to daily fluctuations and changes over days or weeks if there is a
significant alteration of folate ingestion. It would
thus be difficult to be sure that plasma folate taken
some ten to perhaps 20 weeks after the closure of the
neural tube (days 24 to 28) would reflect folate status
at that critical time. By contrast, RCF is recognized as
a superb index of average folate status over a protracted period. This is because the folate placed in the
red cell is done so exclusively during the period of
the production and maturation of the red cell in the
bone marrow. During that period the folate contents
of all red cells is determined by the plasma folate
levels that exist at that time. Once the red cell matures, it neither absorbs any further folate nor loses
folate until its destruction, usually at 120 days. Thus,
RCF reflects the average plasma folate level and the
average status over the previous seven weeks. Therefore, RCF is considered a very stable indication of
folate status.
While the cases in our study had significantly
lower plasma and RCF levels than the controls, the
important question with regard to the hypothesis
being addressed concerns the number of cases that
were likely to be folate deficient at the time of closure
of the neural tube. While we do not have either
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FIGURE 18-1. Regression analysis between log transformed
plasma vitamin B12 and log transformed plasma folate in
controls (top) and cases (bottom).

plasma samples or ReF samples taken during that
critical, one-month period into pregnancy, it seems
reasonable that our ReF values would reflect that
earlier status. It can be seen from the results that some
86% of cases have ReF values in the normal range,

3

4
B

indicating that folate deficiency per se is not the cause
ofNTDs, at least not in the normal meaning of folate
deficiency. These findings would also appear to rule
out the contention of others [12,13J that intestinal
malabsorption of folate is involved in the etiology of
NTDs. Were this the case, one would expect this to
be reflected in a large number of cases, which clearly
they do not (table 18-1).
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Thus, it would appear that the beneficial effect of
folic acid is in overcoming a metabolic block in some
folate-dependent enzyme or transport process. There
are 16 folate-dependent enzymes. We found that, as
with folate, almost all of the cases had plasma vitamin
Bl2 levels in the normal range, indicating that they
were not vitamin B12 deficient (table 18-2). However
logistic regression analysis showed that the plasma
vitamin B12 level was an independent risk factor for
NTDs. We have shown experimentally that plasma
folate and plasma vitamin B12 are not correlated either
in cases or controls (fig. 18-1); the vitamin B12 level is
not simply reflecting plasma folate level, which
would make it a dependent risk factor. Methionine
synthase is the only enzyme that is dependent for
its activity on both folate and vitamin B12 . This
would suggest that the activity of methionine
synthase is directly or indirectly involved in the development of NTDs. Our finding of an abnormality
in homocysteine metabolism in the cases compared
with the controls supports the hypothesis that methionine synthase may be directly or indirectly involved [II}. The effect could be direct in that some
NTDs might be caused by an abnormal methionine
synthase, or indirect in that if there was an abnormality in an enzyme like 5,10 methylenetetrahydrofolate
reductase, variations in activity of the synthase might
determine whether a woman would become a case or
control.
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